SG11201908670SA - Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators - Google Patents

Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators

Info

Publication number
SG11201908670SA
SG11201908670SA SG11201908670SA SG11201908670SA SG 11201908670S A SG11201908670S A SG 11201908670SA SG 11201908670S A SG11201908670S A SG 11201908670SA SG 11201908670S A SG11201908670S A SG 11201908670SA
Authority
SG
Singapore
Prior art keywords
suite
massachusetts
watertown
forma
therapeutics
Prior art date
Application number
Inventor
Anna Ericsson
Neal Green
Gary Gustafson
Bingsong Han
Lancia, Jr
Lorna Mitchell
David Richard
Tatiana Shelekhin
Chase C Smith
Zhongguo Wang
Xiaozhang Zheng
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of SG11201908670SA publication Critical patent/SG11201908670SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

R0 R 1 R 1 ' R9' R10' R 11 ' R ii 0 II N—S—Y—R 4 (I) 0 R 9 R 8 0 R10 R2' (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT ill 1111u°11101VIIIVIIIVIIIolo oloinomonimmom oimIE (10) International Publication Number WO 2018/175474 Al (51) International Patent Classification: (74) Agent: REARICK, John P. et al.; Choate, Hall & Ste- CO7D 487/04 (2006.01) CO7D 519/00 (2006.01) wart LLP, Two International Place, Boston, Massachusetts A61K 31/407 (2006.01) A61P 7/00 (2006.01) 02110 (US). C (21) International Application Number: PCT/US2018/023405 (22) International Filing Date: 20 March 2018 (20.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/473,751 20 March 2017 (20.03.2017) US (71) Applicant: FORMA THERAPEUTICS, INC. [US/US]; 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). (72) Inventors: ERICSSON, Anna; c/o Forma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massa- chusetts 02472 (US). GREEN, Neal; c/o Forma Thera- peutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). GUSTAFSON, Gary; c/o For- ma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Wa- tertown, Massachusetts 02472 (US). HAN, Bingsong; c/ o Forma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). LANCIA, JR., David R.; c/o Forma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). MITCHELL, Lorna; c/o Forma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). RICHARD, David; c/o Forma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). SHELEKHIN, Tatiana; c/o Forma Therapeu- tics, Inc., 500 Arsenal Street, Suite 100, Watertown, Mass- achusetts 02472 (US). SMITH, Chase C.; c/o Forma Ther- apeutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). WANG, Zhongguo; c/o For- ma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Wa- tertown, Massachusetts 02472 (US). ZHENG, Xiaozhang; c/o Forma Therapeutics, Inc., 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) (54) Title: PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS 1-1 (57) : The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds of formula (I) useful as © activators of PKR, as well as various uses of these compounds. PKR activating compounds are useful in the treatment of diseases and disorders associated with PKR and/or PKM2, such as pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia.
SG11201908670S 2017-03-20 2018-03-20 Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators SG11201908670SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762473751P 2017-03-20 2017-03-20
PCT/US2018/023405 WO2018175474A1 (en) 2017-03-20 2018-03-20 Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators

Publications (1)

Publication Number Publication Date
SG11201908670SA true SG11201908670SA (en) 2019-10-30

Family

ID=61911726

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908670S SG11201908670SA (en) 2017-03-20 2018-03-20 Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators

Country Status (32)

Country Link
US (7) US10208052B1 (en)
EP (3) EP3680241A1 (en)
JP (2) JP6594570B2 (en)
KR (2) KR102296703B1 (en)
CN (2) CN109311897B (en)
AR (2) AR111295A1 (en)
AU (4) AU2018240172C1 (en)
BR (1) BR112018075312A2 (en)
CA (1) CA3024181C (en)
CY (2) CY1122393T1 (en)
DK (2) DK3483164T3 (en)
EA (1) EA201992215A1 (en)
ES (2) ES2747768T3 (en)
HR (2) HRP20191665T1 (en)
HU (2) HUE045261T2 (en)
IL (2) IL269447B (en)
LT (2) LT3448859T (en)
MA (3) MA50589A (en)
MD (2) MD3448859T2 (en)
MX (2) MX2018014032A (en)
NZ (2) NZ748072A (en)
PL (2) PL3448859T3 (en)
PT (2) PT3483164T (en)
RS (2) RS59306B1 (en)
RU (3) RU2736217C2 (en)
SA (1) SA519410164B1 (en)
SG (1) SG11201908670SA (en)
SI (2) SI3483164T1 (en)
TN (2) TN2019000290A1 (en)
TW (2) TW202244048A (en)
WO (1) WO2018175474A1 (en)
ZA (1) ZA201906278B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702334A (en) 2012-06-13 2016-11-25 Hoffmann La Roche New diazaspirocycloalkane and azaspirocycloalkane
SG11201500572YA (en) 2012-09-25 2015-02-27 Hoffmann La Roche New bicyclic derivatives
AR095079A1 (en) 2013-03-12 2015-09-16 Hoffmann La Roche DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
MA38982A1 (en) 2013-11-26 2017-09-29 Hoffmann La Roche Novel octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrol-2-yl
EP3122751B1 (en) 2014-03-26 2019-10-30 F.Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
UA118582C2 (en) 2014-03-26 2019-02-11 Ф. Хоффманн-Ля Рош Аг Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA41898A (en) 2015-04-10 2018-02-13 Hoffmann La Roche BICYCLIC QUINAZOLINONE DERIVATIVES
MX2018000511A (en) 2015-09-04 2018-04-24 Hoffmann La Roche Phenoxymethyl derivatives.
RU2018112230A (en) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг BICYCLE COMPOUNDS AS ATX INHIBITORS
AU2016328365B2 (en) 2015-09-24 2020-04-23 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
JP6846414B2 (en) 2015-09-24 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bicyclic compounds as ATX inhibitors
KR20180054634A (en) * 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 As a dual auto-thixin (ATX) / carbonic anhydrase (CA) inhibitor,
CA3053329A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual atx/ca inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
EP3680241A1 (en) * 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2021003187A (en) * 2018-09-19 2021-06-23 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 9x.
US20210346356A1 (en) * 2018-09-19 2021-11-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2020191022A1 (en) * 2019-03-18 2020-09-24 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x
WO2021055863A1 (en) * 2019-09-19 2021-03-25 Forma Therapeutics, Inc. Pyruvate kinase r (pkr) activating compositions
KR20220066272A (en) * 2019-09-19 2022-05-24 포르마 세라퓨틱스 인크. Activation of pyruvate kinase R
US20230159538A1 (en) * 2020-04-01 2023-05-25 Global Blood Therapeutics, Inc. Pyrrolidine-pyrazoles as pyruvate kinase activators
US20220087983A1 (en) * 2020-09-18 2022-03-24 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2023116774A1 (en) 2021-12-21 2023-06-29 赛诺哈勃药业（成都）有限公司 Compound containing bis(azanylylidene) sulfonyl structure and use thereof in medicine
WO2024112764A1 (en) 2022-11-21 2024-05-30 Novo Nordisk Health Care Ag Synthesis of pyrrolo[3,4-c]pyrroles
CN115957219B (en) * 2022-12-27 2024-04-19 北京大学 Application of depolymerizing agent of M2 subtype pyruvate kinase aggregate in preparation of anti-aging drugs

Family Cites Families (362)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007529B1 (en) 1978-07-13 1983-07-20 The Wellcome Foundation Limited Antiprotozoal oxadiazole derivatives, processes for their preparation and pharmaceutical formulations containing them
EP0036711B1 (en) 1980-03-22 1985-12-04 Fbc Limited Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
US4602093A (en) 1984-02-08 1986-07-22 Merck & Co., Inc. Novel substituted imidazoles, their preparation and use
JPS61200544A (en) 1985-03-04 1986-09-05 Toyo Ink Mfg Co Ltd Electrophotographic sensitive body
DE3600390A1 (en) 1986-01-09 1987-07-16 Hoechst Ag DIARYLALKYL-SUBSTITUTED ALKYLAMINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCTS CONTAINING THE SAME
EP0264883A3 (en) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
JPS63165376A (en) 1986-12-27 1988-07-08 Nippon Soda Co Ltd Oxa(thia)diazole derivative and production thereof and acaricidal agent
JPH01108006A (en) 1987-10-21 1989-04-25 Nagasaki Pref Gov Splitting of brittle material
JPH01110376A (en) 1987-10-24 1989-04-27 Mizuno Corp Method for manufacturing bat of fiber-reinforced plastics
KR910001238B1 (en) 1988-02-26 1991-02-26 재단법인 한국화학연구소 Process for the preparation of 0-acyamideoxime derivatives
EP0338372A3 (en) 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5180719A (en) 1988-10-24 1993-01-19 Norwich Eaton Pharmaceuticals, Inc. Antimicrobial quinolonyl lactam esters
GB8900382D0 (en) 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
EP0393607B1 (en) 1989-04-19 1996-02-21 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives having a hetero ring
GB8908875D0 (en) 1989-04-19 1989-06-07 Ici Plc Fungicides
JPH0313040A (en) 1989-06-09 1991-01-22 Sharp Corp Cordless telephone set
KR910009330B1 (en) 1989-10-23 1991-11-11 재단법인 한국화학연구소 Antimicrobial quinoline compounds and the preparation process thereof
KR910009331B1 (en) 1989-10-23 1991-11-11 재단법인 한국화학연구소 Diazabicycloamine compounds and the preparation process thereof
KR910009333B1 (en) 1989-10-23 1991-11-11 재단법인 한국화학연구소 Antimicrobial quinoline compounds and the preparation process thereof
US5030631A (en) 1989-11-27 1991-07-09 Schering Corporation Tricylclic arylsulfonamides
US5747502A (en) 1989-12-13 1998-05-05 Nippon Kayaku Kabushiki Kaisha Process for preparing benzo c!phenanthridinium derivatives, novel compounds prepared by said process, and antitumor agents
JP3036789B2 (en) 1990-06-22 2000-04-24 三井化学株式会社 Novel heterocyclic compounds and pharmaceutical compositions
FR2664592B1 (en) 1990-07-10 1994-09-02 Adir NOVEL DERIVATIVES OF PIPERIDINE, TETRAHYDROPYRIDINE AND PYRROLIDINE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5262565A (en) 1990-11-16 1993-11-16 Eisai Co., Ltd. Naphthalene derivatives
JP2859451B2 (en) 1991-01-11 1999-02-17 太平洋セメント株式会社 Method for producing N-fluoropyridinium salt
DE4121214A1 (en) 1991-06-27 1993-01-14 Bayer Ag 7-AZAISOINDOLINYL CHINOLONE AND NAPHTHYRIDONE CARBONIC ACID DERIVATIVES
JP3038065B2 (en) 1991-11-07 2000-05-08 太平洋セメント株式会社 Method for producing N-fluoropyridinium salt
JPH05196976A (en) 1991-11-18 1993-08-06 Toshiba Corp Organic nonlinear optical element
UA41297C2 (en) 1991-11-25 2001-09-17 Пфайзер, Інк. Indole derivatives, a pharmaceutical composition and a method for treatment
US5480899A (en) 1992-04-30 1996-01-02 Taiho Pharmaceutical Co., Ltd. Oxazolidine derivatives and pharmaceutically acceptable salts thereof
DE4232418A1 (en) 1992-09-28 1994-03-31 Bayer Ag Use of substituted 1,2,4-oxadiazole derivatives for the control of endoparasites, novel substituted 1,2,4-oxadiazole derivatives and processes for their preparation
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
JP3130400B2 (en) 1993-01-13 2001-01-31 信越化学工業株式会社 Polymer scale adhesion inhibitor, and method for producing polymer using the same
JPH07164400A (en) 1993-12-15 1995-06-27 Nec Corp Cutting device for glass board
DE4401108A1 (en) 1994-01-17 1995-07-20 Bayer Ag 1,2,4-oxadiazole derivatives
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
IT1274018B (en) 1994-02-23 1997-07-14 Riace Ets 3,8-DIAZABICYCLE DERIVATIVES (3.2.1.) OCTANO FOR ANALGESIC ACTIVITY
FR2732964B1 (en) 1995-04-14 1997-05-16 Adir NOVEL TRICYCLIC AMIDES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP3830183B2 (en) 1995-09-29 2006-10-04 東京応化工業株式会社 Oxime sulfonate compound and acid generator for resist
JP3275666B2 (en) 1995-10-18 2002-04-15 トヨタ自動車株式会社 Vehicle behavior control device
DE19608316C2 (en) 1996-02-22 2000-11-09 Ivoclar Ag Schaan Functionalized bicyclic (meth) acrylates, process for their preparation and their use ####
KR20000075833A (en) 1997-02-28 2000-12-26 캔디센트 테크날러지스 코퍼레이션 Polycarbonate-containing liquid chemical formulation and method for making polycarbonate film
US6500885B1 (en) 1997-02-28 2002-12-31 Candescent Technologies Corporation Polycarbonate-containing liquid chemical formulation and methods for making and using polycarbonate film
PL336628A1 (en) 1997-05-03 2000-07-03 Smithkline Beecham Plc Derivatives of tetrahydroisoquinoline as modulators of d3 dopamine receptors
JPH1110376A (en) 1997-06-25 1999-01-19 Souei Tsusho Kk Cutting method
WO1999001442A1 (en) 1997-07-02 1999-01-14 Zeneca Limited Triazine derivatives and their use as antibacterial agents
GB9714383D0 (en) 1997-07-08 1997-09-10 Pfizer Ltd Improved process
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6020525A (en) 1998-03-19 2000-02-01 Hoffmann-La Roche Inc. (2S,2'R,3'R)-2-(2,3-dicarboxyl-cyclopropyl)-glycine (DCG-1/4) and 3 H-DCG-1/4 and to process for the preparation thereof
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
AU3012699A (en) 1998-03-26 1999-10-18 Department Of The Army, U.S. Government Substituted aromatic compounds for treatment of antibiotic resistant infections
DE19826671A1 (en) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-oxazoline and 1,3-thiazoline derivatives, processes for their preparation and their use as pesticides
FR2780057B1 (en) 1998-06-18 2002-09-13 Sanofi Sa PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AUPP466598A0 (en) 1998-07-14 1998-08-06 University Of Newcastle Research Associates Limited, The Product and process
TWI250152B (en) 1998-07-21 2006-03-01 Eisai Co Ltd N,N-substituted cyclic amine compounds used as calcium antagonizer
CN1329609A (en) 1998-10-08 2002-01-02 史密丝克莱恩比彻姆有限公司 Tetrahydrobenza epine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
JP2002539119A (en) 1999-03-08 2002-11-19 バイエル アクチェンゲゼルシャフト Thiazolyl urea derivatives and their use as antiviral agents
WO2001010842A2 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6696237B1 (en) 1999-10-26 2004-02-24 Fuji Photo Film Co., Ltd. Photothermographic material
DE19955824A1 (en) 1999-11-20 2001-06-13 Schott Spezialglas Gmbh Method and device for cutting a workpiece made of brittle material
CA2389681C (en) 1999-11-26 2010-11-02 Shionogi & Co., Ltd. Npy y5 antagonist
EP1242083B1 (en) 1999-12-17 2007-03-14 Sanofi-Aventis Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them
DE60119894D1 (en) 2000-01-20 2006-06-29 Eisai Co Ltd PIPERIDINE COMPOUNDS AND THESE MEDICAMENTS CONTAINING
US20020025961A1 (en) 2000-02-04 2002-02-28 Scarborough Robert M. Platelet ADP receptor inhibitors
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP2001261653A (en) 2000-03-17 2001-09-26 Sankio Chemical Co Ltd Method for synthesizing pyridine derivative
WO2001085728A2 (en) 2000-05-08 2001-11-15 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i, j] quinolizines, processes, compositions and methods of treatment
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
CZ20031163A3 (en) 2000-10-26 2004-04-14 Smithkline Beecham P. L. C. Benzoxazinone derivatives, process of their preparation, their use and pharmaceutical composition in which the derivatives are comprised
CA2426952C (en) 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
SE0100326D0 (en) 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
ES2312595T3 (en) 2001-05-23 2009-03-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. PIRUVATO-QUINASA AS A NEW DIANA MOLECULA.
DE10139416A1 (en) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituted aromatic bicycles, process for their preparation and their use as medicaments
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003067332A2 (en) 2002-02-06 2003-08-14 Ciba Specialty Chemicals Holding Inc. Sulfonate derivatives and the use therof as latent acids
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
AU2003280991A1 (en) 2002-07-10 2004-02-02 Japan As Represented By The President Of The University Of Tokyo Method for diagnosis of intestinal-type gastric tumors
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
CA2493625A1 (en) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1527074A1 (en) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CN1678321A (en) 2002-07-29 2005-10-05 里格尔药品股份有限公司 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2003258454A1 (en) 2002-09-06 2004-04-30 Schebo®Biotech Ag Compounds for modulating the glycolosis enzyme complex and/or transaminase complex
JP2004175674A (en) 2002-11-25 2004-06-24 Toyo Ink Mfg Co Ltd Organic electroluminescent element material and organic electroluminescent element using the same
EP1437145A1 (en) 2003-01-07 2004-07-14 Schering AG Enhanced scintigraphic imaging agents for imaging of infection and inflammation
US7189723B2 (en) 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US20070037790A1 (en) 2003-03-11 2007-02-15 Francesca Abrate Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE10316081A1 (en) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity
EP1787982B1 (en) 2003-04-11 2010-05-12 High Point Pharmaceuticals, LLC 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds
WO2004104000A1 (en) 2003-05-23 2004-12-02 Japan Tobacco Inc. Tricyclic condensed ring compound and medical use thereof
EP1633892A4 (en) 2003-06-10 2007-10-24 Univ Boston Detection methods for disorders of the lung
PT1643998E (en) 2003-07-03 2007-11-21 Hoffmann La Roche Dual nk1/nk3 antagonists for treating schizophrenia
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
BRPI0412352A (en) 2003-07-30 2006-09-05 Xenon Pharmaceuticals Inc Process for the preparation of tetrazole derivatives of organo boron and organo aluminum azides
CA2533897A1 (en) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
EP1670802A4 (en) 2003-09-18 2010-07-07 Conforma Therapeutics Corp Novel heterocyclic compounds as hsp90-inhibitors
DE10353910A1 (en) 2003-11-18 2005-06-09 Studiengesellschaft Kohle Mbh Process for the synthesis of optically active piperidines
AR046959A1 (en) 2003-12-18 2006-01-04 Tibotec Pharm Ltd MORFOLINILO CONTAINING BENCIMIDAZOLS AS INHIBITORS OF THE REPLICATION OF RESPIRATORY SYNTHETIC VIRUSES
CA2548666C (en) 2003-12-18 2012-08-07 Tibotec Pharmaceuticals Ltd. Amino-benzimidazoles derivatives as inhibitors of respiratory syncytial virus replication
WO2005058869A1 (en) 2003-12-18 2005-06-30 Tibotec Pharmaceuticals Ltd. Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication
ATE499361T1 (en) 2003-12-18 2011-03-15 Tibotec Pharm Ltd 5-OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS
DE602004031776D1 (en) 2003-12-18 2011-04-21 Tibotec Pharm Ltd PIPERIDINAMINO BENZIMIDAZOLE DERIVATIVES AL RESPIRATORY SYNCYTIALVIRUS REPLICATION INHIBITORS
US7422837B2 (en) 2004-02-16 2008-09-09 Fujifilm Corporation Photosensitive composition
JP4845873B2 (en) 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド Bicyclic and bridged nitrogen heterocycles
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2005094834A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
EP1725238A4 (en) 2004-03-17 2009-04-01 Glaxo Group Ltd M 3 muscarinic acetylcholine receptor antagonists
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
TWI391387B (en) 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd Indole derivative having piperidine ring
US7842460B2 (en) 2004-06-21 2010-11-30 Progenra Inc. Method for assessing proteolytic enzyme activity using ubiquitin fusion substrate
CN101014598B (en) 2004-06-21 2012-06-13 默沙东公司 Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
DE102004039789A1 (en) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals
US20080261873A1 (en) 2004-08-18 2008-10-23 Elixir Pharmaceuticals, Inc. Growth-Hormone Secretagogues
DE102004041163A1 (en) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie New compounds with antibacterial activity
JP4958784B2 (en) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
AR051093A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
WO2006038172A1 (en) 2004-10-05 2006-04-13 Actelion Pharmaceuticals Ltd New piperidine antibiotics
JP2008521805A (en) 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド Cardiotonic compounds having inhibitory activity against β-adrenergic receptors and phosphodiesterases
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
GT200600046A (en) 2005-02-09 2006-09-25 COMBINATION THERAPY
NZ588960A (en) 2005-02-25 2012-06-29 Serenex Inc Tetrahydroindolone and tetrahydroindazolone derivatives
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
CN101155583B (en) 2005-04-07 2011-01-19 默沙东公司 Mitotic kinesin inhibitors
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
US8329694B2 (en) 2005-06-24 2012-12-11 Toyama Chemical Co., Ltd. Quinoxalinones as antibacterial composition
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
BRPI0613452A2 (en) 2005-07-11 2011-01-11 Sanofi Aventis 2,4-dianilino pyrimidines derivatives, their preparation as pharmaceuticals, pharmaceutical compositions and notably as ikk inhibitors
DK1910384T3 (en) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc IMIDAZO [2,1-B] THIAZOL DERIVATIVES AS SIRTUINE MODULATING COMPOUNDS
WO2007042325A1 (en) 2005-10-13 2007-04-19 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibacterial active 5-chinolin derivative
GB0600967D0 (en) 2006-01-18 2006-03-01 Imp Innovations Ltd Methods
JP5111398B2 (en) 2006-01-25 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション Aminocyclohexanes as dipeptidyl peptidase IV inhibitors for the treatment or prevention of diabetes
AU2007211508B2 (en) 2006-02-03 2012-08-23 Nicox Science Ireland Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
JP5161795B2 (en) 2006-02-15 2013-03-13 メルク・シャープ・エンド・ドーム・コーポレイション Aminotetrahydropyran as a dipeptidyl peptidase IV inhibitor for the treatment or prevention of diabetes
JP2010519171A (en) 2006-02-17 2010-06-03 メモリー・ファーマシューティカルズ・コーポレイション Compound having 5-HT6 receptor affinity
JP2007246885A (en) 2006-02-20 2007-09-27 Toyo Ink Mfg Co Ltd Photo functional material
TW200806669A (en) 2006-03-28 2008-02-01 Merck & Co Inc Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2007136714A2 (en) 2006-05-16 2007-11-29 Gilead Sciences, Inc. Integrase inhibitors
WO2007136603A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
DE602007009221D1 (en) 2006-05-18 2010-10-28 Hoffmann La Roche THIAZOLOPYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ANTAGONISTS ON THE ADENOSINE A2B RECEPTOR
JP2009538316A (en) 2006-05-26 2009-11-05 カラ セラピューティクス インコーポレイテッド N-oxide of kappa opioid receptor peptide
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP2007328090A (en) 2006-06-07 2007-12-20 Fujifilm Corp Photosensitive composition, photosensitive film, pattern forming method and printed circuit board
ES2645095T3 (en) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through the inhibition of Hsp90
JP2008031064A (en) 2006-07-27 2008-02-14 Astellas Pharma Inc Diacylpiperazine derivative
WO2008094203A2 (en) 2006-08-03 2008-08-07 Microbiotix, Inc. Polar ester prodrugs of heterocyclic hybrid antibacterial compounds and salts thereof
AU2007281911B2 (en) 2006-08-04 2014-02-06 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
JP2008063256A (en) 2006-09-06 2008-03-21 Astellas Pharma Inc beta-AMINO ACID DERIVATIVE
WO2008032905A1 (en) 2006-09-13 2008-03-20 Hurim Biocell Co., Ltd. Genes involved in differentiation of human stem cell lines and the microarray kit containing these genes
US7875603B2 (en) 2006-09-21 2011-01-25 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
TWI404532B (en) 2006-11-02 2013-08-11 Targacept Inc Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
EP2064228B1 (en) 2006-11-10 2012-08-29 Cara Therapeutics, Inc. Synthetic peptide amides
FR2910298A1 (en) 2006-12-20 2008-06-27 Oreal Composition for coloring keratinic fibers, especially hair, comprises a fluorescent dye or optical brightener and two silicones that react together by hydrosilylation, condensation or crosslinking
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
NZ577348A (en) 2006-12-28 2012-04-27 Abbott Lab Inhibitors of poly(adp-ribose)polymerase
PL2069324T3 (en) 2007-03-20 2014-01-31 Curis Inc Fused amino pyridine as hsp90 inhibitors
WO2008120003A1 (en) 2007-04-03 2008-10-09 Astrazeneca Ab Substituted piperidines for use in the treatment of bacterial infections
BRPI0810858A2 (en) 2007-04-27 2014-10-29 Sanofi Aventis 2-HETEROARYL-PYROLLO [3,4-C] PIRROL DERIVATIVES AND THEIR USES AS SCD INHIBITORS
WO2008139585A1 (en) 2007-05-10 2008-11-20 Toray Engineering Co., Ltd. Mechanism for causing early crack
WO2009001126A1 (en) 2007-06-27 2008-12-31 Astrazeneca Ab Substituted piperidine derivatives and their use as antibaterial agents
FR2918061B1 (en) 2007-06-28 2010-10-22 Sanofi Aventis 6-CYCLOAMINO-3- (PYRIDIN-4-YL) IMIDAZO-1,2-B1-PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
FR2918986B1 (en) 2007-07-19 2009-09-04 Sanofi Aventis Sa 6-CYCLOAMINO-3- (PYRIDAZIN-4-YL) IMIDAZO [1,2-B] -PYRIDAZINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP2019318A1 (en) 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
WO2009025781A1 (en) 2007-08-16 2009-02-26 Beth Israel Deaconess Medical Center Activators of pyruvate kinase m2 and methods of treating disease
AU2008289573B2 (en) 2007-08-21 2013-05-16 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
ES2524787T3 (en) 2007-11-15 2014-12-12 Msd Italia S.R.L. Pyridazinone derivatives as PARP inhibitors
WO2009067541A2 (en) 2007-11-20 2009-05-28 Gilead Sciences, Inc. Integrase inhibitors
TW200938203A (en) 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
JP5258280B2 (en) 2007-12-18 2013-08-07 富士フイルム株式会社 Pigment dispersion composition, photosensitive resin composition, color filter and method for producing the same
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926555B1 (en) 2008-01-22 2010-02-19 Sanofi Aventis BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
AR070221A1 (en) 2008-01-23 2010-03-25 Astrazeneca Ab DERIVATIVES OF FTALAZINONA POLYMERASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME TO PREVENT AND / OR TREAT CANCERIGENE TUMORS, ISCHEMICAL INJURIES AND OTHER ASSOCIATED DISEASES.
DE102008010661A1 (en) 2008-02-22 2009-09-03 Dr. Felix Jäger und Dr. Stefan Drinkuth Laborgemeinschaft OHG Preparing pyridin-2-boronic acid compounds, useful e.g. to treat multiple myeloma, comprises preparing a pyridin-2-borate compound, purifying the pyridin-2-borate compound; and hydrolyzing the purified pyridin-2-borate compound
JP2009212473A (en) 2008-03-06 2009-09-17 Fujifilm Corp Metal polishing liquid, and chemical mechanical polishing method
JP2011516442A (en) 2008-04-04 2011-05-26 ビオマリン アイジーエー リミテッド Compounds for treating muscular dystrophy
JP5436544B2 (en) 2008-05-08 2014-03-05 ノヴァ サウスイースタン ユニバーシティ− Inhibitors specific for vascular endothelial growth factor receptor
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
CA2734744A1 (en) 2008-08-20 2010-02-25 Michael Eissenstat Hcv protease inhibitors
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
WO2010028761A1 (en) 2008-09-09 2010-03-18 Sanofi-Aventis 2-heteroaryl-pyrrolo [3, 4-c]pyrrole derivatives and the use thereof as scd inhibitors
WO2010042867A2 (en) 2008-10-09 2010-04-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2012509309A (en) 2008-11-21 2012-04-19 ファイザー・インク 1-oxa-8-azaspiro [4.5] decane-8-carboxamide compounds as FAAH inhibitors
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
JP2010192782A (en) 2009-02-20 2010-09-02 Toyo Ink Mfg Co Ltd Material for photoelectric conversion element, and photoelectric conversion element
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2740424T3 (en) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Methods and compositions for disorders related to cell proliferation
TW201041868A (en) 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
WO2010108268A1 (en) 2009-03-23 2010-09-30 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP5756457B2 (en) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
DK2427441T3 (en) 2009-05-04 2017-03-20 Agios Pharmaceuticals Inc PKM2 Activators for use in the treatment of cancer
WO2010132599A1 (en) 2009-05-14 2010-11-18 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
EP2432779A1 (en) 2009-05-22 2012-03-28 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
US8377639B2 (en) 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
WO2011002816A1 (en) 2009-06-29 2011-01-06 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
WO2012174126A1 (en) 2011-06-13 2012-12-20 Universyty Of Medicine And Dentistry Of New Jesey METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY
EP2467142B1 (en) 2009-08-17 2016-09-21 Memorial Sloan-Kettering Cancer Center 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders
WO2011025690A1 (en) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
WO2011037793A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2011044377A2 (en) 2009-10-09 2011-04-14 Cell Point, Llc Chelator-targeting ligand conjugates for cardiovascular imaging
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
ES2594402T3 (en) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Methods and compositions for disorders related to cell proliferation
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
CN102666838B (en) 2009-11-18 2018-04-10 麦兰特公司 For efficiently producing the engineered microorganisms of chemicals
KR20110096442A (en) 2010-02-22 2011-08-30 주식회사 이엔에프테크놀로지 Color resin resist used in the preparation of color filter
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN101812063B (en) 2010-03-18 2012-04-25 中国医学科学院医药生物技术研究所 Alpha-naphthalenesulfonamide base quintuple heterocyclic compound and anti-tumor activity thereof
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
UY33288A (en) * 2010-03-25 2011-10-31 Glaxosmithkline Llc INDOLINE DERIVATIVES INHIBITORS OF THE PROTEIN QUINASA R OF THE ENDOPLASMATIC RETICLE
WO2011137089A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
JP2011246649A (en) 2010-05-28 2011-12-08 Mitsubishi Chemicals Corp Pigment dispersion, coloring resin composition, color filter, liquid crystal display, and organic el display
RU2560163C2 (en) 2010-06-30 2015-08-20 Фуджифилм Корпорэйшн New nicotinamide derivative or salt thereof
ES2525581T3 (en) 2010-07-12 2014-12-26 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage-dependent sodium channel inhibitors
JP2013532186A (en) 2010-07-12 2013-08-15 ファイザー・リミテッド Compound
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CN102372716A (en) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazone derivative, its preparation method and application in medicine thereof
CN102372706A (en) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazinone derivative, its preparation method and application in medicament
EP2632920A1 (en) 2010-10-27 2013-09-04 Dynamix Pharmaceuticals Ltd. Sulfonamides for the modulation of pkm2
EP2640366A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US20120134979A1 (en) 2010-11-22 2012-05-31 Yang Xia Methods and compositions for the treatment of sickle cell disease
CN103459384A (en) 2010-11-24 2013-12-18 埃克塞里艾克西斯公司 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture
EP2646428B1 (en) 2010-12-02 2016-06-01 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivatives, preparation processes and medical uses thereof
EP2651404B1 (en) 2010-12-14 2015-10-14 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors
EP2651898B1 (en) 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Novel n-(4-(azetidine-1-carbonyl)phenyl)-(hetero-)arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
ES2569712T3 (en) 2010-12-21 2016-05-12 Agios Pharmaceuticals, Inc. PKM2 bicyclic activators
TWI549947B (en) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 Therapeutic compounds and compositions
WO2012092426A1 (en) 2010-12-30 2012-07-05 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
EP2658557A1 (en) 2010-12-31 2013-11-06 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
JP2012188475A (en) 2011-03-09 2012-10-04 Toyo Ink Sc Holdings Co Ltd Pigment dispersant and pigment composition, coloring composition, and color filter using the same
JP2012188474A (en) 2011-03-09 2012-10-04 Toyo Ink Sc Holdings Co Ltd Pigment dispersant and pigment composition, coloring composition, and color filter using the same
CN102206217A (en) 2011-03-17 2011-10-05 盛世泰科生物医药技术(苏州)有限公司 Heterocyclic compounds for treating or preventing diabetes mellitus as dipeptidyl peptidase inhibitor
US8685966B2 (en) 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
LT3406251T (en) 2011-05-03 2024-02-12 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
CA2834692A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
US9388164B2 (en) 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
ES2668213T3 (en) * 2011-05-03 2018-05-17 Agios Pharmaceuticals, Inc. Use of pyruvate kinase activators to increase the lifespan of red blood cells and treat anemia
US9181231B2 (en) 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
US20120302609A1 (en) 2011-05-25 2012-11-29 Dynamix Pharmaceuticals Ltd. Pyrazolines for the Modulation of PKM2
GB201108825D0 (en) 2011-05-25 2011-07-06 Univ Dundee Morpholino compounds, uses and methods
RU2472794C1 (en) * 2011-05-25 2013-01-20 Федеральное государственное образовательное учреждение высшего профессионального образования Астраханский государственный технический университет (ФГОУ ВПО АГТУ) Novel bicyclic pyrrolidine derivatives having antioxidant activity and method for production thereof
KR20140034861A (en) 2011-06-29 2014-03-20 머크 샤프 앤드 돔 코포레이션 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
DK2729806T3 (en) 2011-07-08 2017-05-15 Sloan-Kettering Inst For Cancer Res APPLICATIONS OF MARKED HSP90 INHIBITORS
JO3611B1 (en) 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones
CN102952139B (en) 2011-08-30 2016-08-10 上海药明康德新药开发有限公司 Trans-3a-fluoropyrrolidine [3,4-C] cycle compound and preparation method thereof
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
US20140249150A1 (en) 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
JP5468056B2 (en) 2011-12-15 2014-04-09 富士フイルム株式会社 Electrophoretic composition, microcapsule, and electrophoretic display element
PE20221914A1 (en) 2011-12-28 2022-12-23 Global Blood Therapeutics Inc SUBSTITUTE BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102826A1 (en) 2012-01-04 2013-07-11 Pfizer Limited N-aminosulfonyl benzamides
JP2015083542A (en) 2012-02-08 2015-04-30 大日本住友製薬株式会社 Three substituted proline derivative
JP5895583B2 (en) 2012-02-21 2016-03-30 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, LIGHTING DEVICE AND DISPLAY DEVICE, AND METHOD FOR PRODUCING ORGANIC ELECTROLUMINESCENT ELEMENT
US9493481B2 (en) 2012-02-23 2016-11-15 Vanderbilt University Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
CA2865509A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfone and sulfoxide derivatives
WO2013155223A1 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
CA2874621A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US20150150935A1 (en) 2012-06-05 2015-06-04 Cara Therapeutics, Inc. Peripheral kappa receptor agonists for reducing pain and inflammation
BR112015000187A2 (en) 2012-07-06 2017-06-27 Genentech Inc benzamides substituted with n and methods of use thereof
CN103570722A (en) 2012-07-19 2014-02-12 中国科学院上海药物研究所 Fused ring pyridazinone compounds, preparation method and uses thereof
CN104640843A (en) 2012-07-19 2015-05-20 大日本住友制药株式会社 1-(cycloalkyl-carbonyl)proline derivative
WO2014018355A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
MX367309B (en) 2012-08-10 2019-08-14 Janssen Sciences Ireland Uc New antibacterial compounds.
AR092211A1 (en) 2012-09-24 2015-04-08 Merck Patent Ges Mit Beschränkter Haftung HYDROPIRROLOPIRROL DERIVATIVES
SG11201500572YA (en) 2012-09-25 2015-02-27 Hoffmann La Roche New bicyclic derivatives
DK2909181T3 (en) 2012-10-16 2017-11-20 Tolero Pharmaceuticals Inc PKM2 modulators and methods for their use
TWI500613B (en) * 2012-10-17 2015-09-21 Cadila Healthcare Ltd Novel heterocyclic compounds
MX2015005841A (en) * 2012-11-08 2016-01-08 Agios Pharmaceuticals Inc Therapeutic compounds and compositions and their use as pkm2 modulators.
EP2935247B1 (en) 2012-12-21 2019-08-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
PT2938598T (en) 2012-12-31 2017-02-07 Cadila Healthcare Ltd Substituted phthalazin-1(2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
RU2015136673A (en) 2013-01-31 2017-03-10 Каприон Протеомикс Инк. SUGAR DIABETES BIOMARKERS TYPE 2 AND THEIR APPLICATION
EP2959016A4 (en) 2013-02-21 2016-10-12 Toma Biosciences Inc Methods, compositions, and kits for nucleic acid analysis
AR095079A1 (en) 2013-03-12 2015-09-16 Hoffmann La Roche DERIVATIVES OF OCTAHIDRO-PIRROLO [3,4-C] -PIRROL AND PIRIDINA-FENILO
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
JP6473133B2 (en) 2013-03-15 2019-02-20 アラクセス ファーマ エルエルシー Covalent inhibitor of KRASG12C
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237348C1 (en) 2013-03-15 2019-02-07 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014172638A2 (en) 2013-04-18 2014-10-23 Brandeis University Inhibitors of deubiquitinating proteases
US9662324B2 (en) 2013-05-01 2017-05-30 Academia Sinica Methods and compositions for treating β-thalassemia and sickle cell disease
KR102084185B1 (en) 2013-08-29 2020-03-04 주식회사 대웅제약 Tetrahydrocyclopentapyrrole derivatives and method for preparation thereof
KR102253719B1 (en) 2013-09-11 2021-05-18 메르크 파텐트 게엠베하 Heterocyclic compounds
EP3046920B1 (en) 2013-09-20 2021-08-04 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2015048336A2 (en) 2013-09-25 2015-04-02 Institute For Systems Biology Markers for amyotrophic lateral sclerosis (als) and presymptomatic alzhimer's disease (psad)
WO2015051230A1 (en) 2013-10-04 2015-04-09 Drexel University Novel compositions useful for inhibiting hiv-1 infection and methods using same
CN105705504A (en) 2013-10-10 2016-06-22 密歇根大学董事会 Deubiquitinase inhibitors and methods for use of the same
EA202092627A1 (en) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
PE20161247A1 (en) 2013-11-27 2016-11-30 Genentech Inc SUBSTITUTED BENZAMIDES AND METHODS FOR USING THEM
EP3083995A2 (en) 2013-12-17 2016-10-26 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Means and methods for typing a breast cancer patient and assigning therapy based on the typing
WO2015116061A1 (en) 2014-01-29 2015-08-06 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
EP3110821B1 (en) 2014-02-28 2019-10-30 Corning Incorporated Diketopyrrolopyrrole semiconducting materials, processes for their preparation and uses thereof
UA118582C2 (en) 2014-03-26 2019-02-11 Ф. Хоффманн-Ля Рош Аг Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN105037367A (en) 2014-04-18 2015-11-11 四川海思科制药有限公司 Amino six-membered ring derivative and application thereof in medicines
CN105085528A (en) 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 Aminotetrahydropyran derivative as dipeptidyl peptidase-IV inhibitor
DK3149204T3 (en) 2014-05-28 2021-10-25 Predictomics Ab In vitro toxicogenomics for toxicity prediction
JP6535034B2 (en) 2014-06-17 2019-06-26 スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド Aminopyran ring derivative and composition and use thereof
CN105294694B (en) 2014-06-18 2019-01-04 四川海思科制药有限公司 Amino hexatomic ring analog derivative and its application in medicine
AU2015286635A1 (en) 2014-07-11 2017-01-19 Intervet Inc. Use of anthelmintic agents against Dirofilaria immitis
CN106659720A (en) 2014-07-11 2017-05-10 英特维特国际股份有限公司 Use of anthelmintic agents against dirofilaria immitis
US9862725B2 (en) 2014-07-21 2018-01-09 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
WO2016014522A1 (en) 2014-07-21 2016-01-28 Brandeis University Inhibitors of deubiquitinating proteases
US20170216434A1 (en) 2014-08-05 2017-08-03 Wayne State University Compositions and methods for treatment of sickle cell disease
KR101837565B1 (en) 2014-08-06 2018-03-12 삼성에스디아이 주식회사 Organic compound and organic optoelectric device and display device
US20170283440A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Carm1 inhibitors and uses thereof
JP2017530959A (en) 2014-09-17 2017-10-19 エピザイム，インコーポレイティド CARM1 inhibitors and uses thereof
AU2015317632B2 (en) 2014-09-17 2022-01-13 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
WO2016047592A1 (en) 2014-09-22 2016-03-31 国立研究開発法人科学技術振興機構 Anti-influenza virus agent, and screening method for anti-influenza virus agent
WO2016046837A1 (en) * 2014-09-22 2016-03-31 Cadila Healthcare Limited An improved process for preparation of pyrrolo[3,4- c] pyrrole compounds and intermediates thereof
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
WO2016168647A1 (en) 2015-04-17 2016-10-20 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibotrs
US10550150B2 (en) 2015-05-11 2020-02-04 Cadila Healthcare Limited Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist
WO2016196816A1 (en) 2015-06-03 2016-12-08 The University Of North Carolina At Chapel Hill Photoredox-catalyzed direct c-h functionalization of arenes
LT3307271T (en) 2015-06-11 2023-10-25 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
CN105153119B (en) 2015-09-11 2019-01-01 广州必贝特医药技术有限公司 Pyridine pyrimidinamine compound or pyridine pyridyl amine compound and its application
RU2018112230A (en) 2015-09-24 2019-10-30 Ф. Хоффманн-Ля Рош Аг BICYCLE COMPOUNDS AS ATX INHIBITORS
KR20180054634A (en) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 As a dual auto-thixin (ATX) / carbonic anhydrase (CA) inhibitor,
CN105254628B (en) 2015-11-13 2017-06-23 南京华威医药科技开发有限公司 Pyrazolopyridine anti-tumor compounds and its preparation method and application
CN105348286B (en) 2015-11-25 2018-12-18 中山奕安泰医药科技有限公司 A kind of 2- methyl sulphonyl -2,4, the preparation method of 5,6- nafoxidines [3,4-c] pyrazoles benzene sulfonate
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
TWI825524B (en) 2016-05-12 2023-12-11 美商全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1hpyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
MA44037B1 (en) 2016-06-06 2020-03-31 Arena Pharm Inc Beta 3 adrenergic receptor modulators useful in the treatment or prevention of disorders associated therewith
MX2019002728A (en) 2016-09-09 2019-08-16 Tg Therapeutics Inc Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers.
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2018109277A1 (en) 2016-12-14 2018-06-21 Åbo Akademi University Diagnosis of parkinson's disease on the basis of decreased overall translation
US9744145B1 (en) 2017-01-16 2017-08-29 Macau University Of Science And Technology Methods for treating lung cancer
EP3680241A1 (en) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
CN106928222B (en) 2017-04-25 2019-08-23 淮阴师范学院 A kind of preparation method of 3- alkyl Indoli zine derivatives
TWI796353B (en) 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 Pyruvate kinase modulators and use thereof
WO2019099651A1 (en) 2017-11-16 2019-05-23 Agios Pharmaceuticals, Inc. Methods of using deuterated pyruvate kinase activators
MD3713919T2 (en) 2017-11-22 2024-02-29 Agios Pharmaceuticals Inc Crystalline forms of N-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
US11339172B2 (en) 2017-12-06 2022-05-24 Arena Pharmaceuticals, Inc. Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20210346356A1 (en) 2018-09-19 2021-11-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
MX2021003187A (en) 2018-09-19 2021-06-23 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 9x.
JP7164400B2 (en) 2018-10-30 2022-11-01 株式会社オカムラ Furniture with top plate
PL3880654T3 (en) 2018-11-19 2022-04-25 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin
US20220041597A1 (en) 2018-12-26 2022-02-10 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x
WO2020191022A1 (en) 2019-03-18 2020-09-24 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x
CN109912610B (en) 2019-04-04 2020-06-23 石家庄诚志永华显示材料有限公司 Organic compound and application thereof in preparation of organic electroluminescent element
KR20220066272A (en) 2019-09-19 2022-05-24 포르마 세라퓨틱스 인크. Activation of pyruvate kinase R
US20220304987A1 (en) 2021-03-19 2022-09-29 Forma Therapeutics, Inc. Activating pyruvate kinase r

Also Published As

Publication number Publication date
US20210246143A1 (en) 2021-08-12
AU2018240172C1 (en) 2019-10-24
BR112018075312A2 (en) 2019-10-01
ES2747768T3 (en) 2020-03-11
AU2021201244B2 (en) 2022-10-20
TN2020000045A1 (en) 2021-10-04
AU2019206013B2 (en) 2020-12-03
US12071440B2 (en) 2024-08-27
LT3483164T (en) 2020-05-11
US10836771B2 (en) 2020-11-17
CA3024181A1 (en) 2018-09-27
EA201992215A1 (en) 2020-02-06
AU2018240172B2 (en) 2019-05-16
RS59306B1 (en) 2019-10-31
TW202244048A (en) 2022-11-16
TW201837041A (en) 2018-10-16
AU2019206013A1 (en) 2019-08-01
KR20190092597A (en) 2019-08-07
RU2019137023A3 (en) 2020-04-30
RU2707751C1 (en) 2019-11-29
US11396513B2 (en) 2022-07-26
ES2788856T3 (en) 2020-10-23
WO2018175474A1 (en) 2018-09-27
MA50589A (en) 2021-09-15
EP3483164A1 (en) 2019-05-15
KR102296703B1 (en) 2021-09-01
CY1122393T1 (en) 2021-01-27
ZA201906278B (en) 2021-01-27
EP3483164B1 (en) 2020-03-04
US10208052B1 (en) 2019-02-19
SI3483164T1 (en) 2020-08-31
EP3680241A1 (en) 2020-07-15
MA44795B1 (en) 2019-09-30
CN109311897B (en) 2021-07-20
AR115993A2 (en) 2021-03-17
JP2019206587A (en) 2019-12-05
RU2736217C2 (en) 2020-11-12
PL3448859T3 (en) 2020-02-28
IL289175A (en) 2022-02-01
PT3483164T (en) 2020-05-14
JP6594570B2 (en) 2019-10-23
EP3448859B1 (en) 2019-07-10
AU2022241506A1 (en) 2022-10-27
CY1123897T1 (en) 2022-03-24
HUE049979T2 (en) 2020-11-30
NZ748072A (en) 2020-06-26
PT3448859T (en) 2019-10-25
MA45614B1 (en) 2020-04-30
MA44795A (en) 2019-03-06
KR20180135494A (en) 2018-12-20
US20210017184A1 (en) 2021-01-21
DK3483164T3 (en) 2020-03-23
MX2018014032A (en) 2019-08-21
EP3448859A1 (en) 2019-03-06
PL3483164T3 (en) 2020-08-24
US20190218221A1 (en) 2019-07-18
HUE045261T2 (en) 2019-12-30
US20200069643A1 (en) 2020-03-05
HRP20191665T1 (en) 2020-02-07
CN113456634A (en) 2021-10-01
RU2019137023A (en) 2019-12-24
CA3024181C (en) 2023-06-13
SA519410164B1 (en) 2022-03-10
AR111295A1 (en) 2019-06-26
US20200031839A1 (en) 2020-01-30
US10472371B2 (en) 2019-11-12
US20240083901A1 (en) 2024-03-14
US11649242B2 (en) 2023-05-16
JP7213775B2 (en) 2023-01-27
MX2020013936A (en) 2022-12-01
NZ763766A (en) 2023-07-28
MD3448859T2 (en) 2020-03-31
LT3448859T (en) 2019-10-25
TN2019000290A1 (en) 2021-05-07
AU2021201244A1 (en) 2021-03-11
KR102007135B1 (en) 2019-08-02
HRP20200752T1 (en) 2020-07-24
AU2018240172A1 (en) 2018-11-29
RU2020136402A (en) 2022-05-06
CN109311897A (en) 2019-02-05
DK3448859T3 (en) 2019-09-23
US11014927B2 (en) 2021-05-25
JP2019521090A (en) 2019-07-25
RS60209B1 (en) 2020-06-30
IL269447A (en) 2019-11-28
TWI772389B (en) 2022-08-01
IL269447B (en) 2022-01-01
MD3483164T2 (en) 2020-07-31
SI3448859T1 (en) 2020-02-28

Similar Documents

Publication Publication Date Title
SG11201908670SA (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201809082WA (en) Nlrp3 modulators
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201805533QA (en) Composition and methods for cryopreservation of hutc
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201811712QA (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201811671XA (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy
SG11201804587QA (en) Isoindole compounds